Improved COBAS TaqMan Hepatitis C Virus Test (Version 2.0) for Use with the High Pure System: Enhanced Genotype Inclusivity and Performance Characteristics in a Multisite Study - Wikidata - awgldk - TriplyDB

Improved COBAS TaqMan Hepatitis C Virus Test (Version 2.0) for Use with the High Pure System: Enhanced Genotype Inclusivity and Performance Characteristics in a Multisite Study

Improved COBAS TaqMan Hepatitis C Virus Test (Version 2.0) for Use with the High Pure System: Enhanced Genotype Inclusivity and Performance Characteristics in a Multisite Study

http://www.wikidata.org/entity/Q24289102

about

Differences between Two Real-Time PCR-Based Hepatitis C Virus (HCV) Assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and One Signal Amplification Assay (Versant HCV RNA 3.0) for RNA Detection and Quantification A Novel Diagnostic Target in the Hepatitis C Virus Genome Abbott RealTime Hepatitis C Virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV Assays for Prediction of Sustained Virological Response to Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Detection and Quantification of Hepatitis C Virus (HCV) by MultiCode-RTx Real-Time PCR Targeting the HCV 3' Untranslated Region Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin.Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection Comparison of Two Commercial Automated Nucleic Acid Extraction and Integrated Quantitation Real-Time PCR Platforms for the Detection of Cytomegalovirus in Plasma Performance evaluation of the new Roche cobas AmpliPrep/cobas TaqMan HCV test, version 2.0, for detection and quantification of hepatitis C virus RNA.Comparison of the Abbott Realtime HIV-1 and HCV viral load assays with commercial competitor assays.The COBAS ® TaqMan ® hepatitis C virus assays: automated systems for accurate and sensitive viral load quantification.Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection.European Multicenter Study on Analytical Performance of DxN Veris System HCV Assay Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C.High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection Use of chimeric influenza viruses as a novel internal control for diagnostic rRT-PCR assays.An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay.Performance of the Abbott RealTime and Roche Cobas TaqMan hepatitis C virus (HCV) assays for quantification of HCV genotypes.Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C.Seronegative hepatitis C virus infection in patients with lymphoproliferative disorders.Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected wi HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a.Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b.

P2860

Q27487396-AA3929CB-06C3-43C6-8A22-33AB99A6D371 Q27487878-0DF596D5-7F64-4BE3-AEC4-6E2F03439A9A Q27487942-A88C9B1E-4DE3-44A7-9169-CFA1BF52204E Q27489128-15B835DA-3914-4B78-8AAE-7109648A228B Q34488497-F98EA284-E78F-46AB-B3F7-5FF9307BF91B Q34506788-90920ED7-7985-4597-9D09-C56E56699CB1 Q36096112-E44BC14F-DBE8-4979-8F38-DD7D21ECEEE2 Q36506264-F8AD1BA0-4F7A-4F0E-97E7-3E792CE47D23 Q37206232-F5B30F72-12FE-48FA-A63C-AD8CCB7B4764 Q39694201-BBFD04BA-F3D1-4493-9DCF-711AFAE12857 Q39973981-300B86DD-4510-4FDF-8089-6522761395A2 Q40348977-55647956-9CB2-40B9-B274-5FAD159A2431 Q40529775-B86206D7-BF72-4F03-A8BC-B4E42CE9F239 Q40720239-2C756041-D99F-407D-A727-2BEB2E3CEE14 Q40829360-D6BF4DBC-4437-4862-85DC-6B5A7074E6D1 Q41208292-3CFCCC2B-432F-492D-A000-530276B19447 Q41476752-F02ED9F7-7355-45BF-B9DB-17875C1751A4 Q42143350-354C3CBD-80BE-4D77-8078-A170B06958AB Q42202049-9A7CCACA-3270-4059-899C-8D3915D910F1 Q42243752-C83FF767-ABA0-4D44-AF49-24977FE043FA Q42986231-E124A7D9-02C5-4303-890F-9B0320B63BEB Q43000460-6BDCD83F-47D3-494F-96BD-87847BE33603 Q43039450-D50166DE-4442-4849-A7B4-801EB5C06FE6 Q43042514-98E93528-F489-4A19-88A1-3C94534E3DBB

P2860

Improved COBAS TaqMan Hepatitis C Virus Test (Version 2.0) for Use with the High Pure System: Enhanced Genotype Inclusivity and Performance Characteristics in a Multisite Study

http://www.wikidata.org/entity/Q24289102

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Improved COBAS TaqMan Hepatiti ...... teristics in a Multisite Study

@ast

Improved COBAS TaqMan Hepatiti ...... teristics in a Multisite Study

@en

Improved COBAS TaqMan Hepatiti ...... teristics in a Multisite Study

@en-gb

Improved COBAS TaqMan Hepatiti ...... teristics in a Multisite Study

@nl

type

label

Improved COBAS TaqMan Hepatiti ...... teristics in a Multisite Study

@ast

Improved COBAS TaqMan Hepatiti ...... teristics in a Multisite Study

@en

Improved COBAS TaqMan Hepatiti ...... teristics in a Multisite Study

@en-gb

Improved COBAS TaqMan Hepatiti ...... teristics in a Multisite Study

@nl

altLabel

Improved COBAS TaqMan hepatiti ...... teristics in a multisite study

@en

prefLabel

Improved COBAS TaqMan Hepatiti ...... teristics in a Multisite Study

@ast

Improved COBAS TaqMan Hepatiti ...... teristics in a Multisite Study

@en

Improved COBAS TaqMan Hepatiti ...... teristics in a Multisite Study

@en-gb

Improved COBAS TaqMan Hepatiti ...... teristics in a Multisite Study

@nl

P1433

Q24289102-E9EC96AF-B3B7-4FD3-B888-BCDBC2AD4AC3

P1476

Q24289102-1520D005-718D-46AD-9896-471EB61BF584

P2093

Q24289102-079A8B3B-3606-49C8-B740-8BAE01281145

Q24289102-08907B63-3A50-4A20-B33B-E68DB59E8669

Q24289102-08B6E89C-EC56-4AB5-8F71-E91AD6A62BC4

Q24289102-1046BA72-F2A3-4CBB-84CF-352AA426357D

Q24289102-1127EB78-13D2-4B82-81A3-1B0CDD4A2F86

Q24289102-26479554-61EA-42B6-AB18-EEDAB18788BC

Q24289102-528BFA1B-45DA-45B1-AAB6-D8844E7F753B

Q24289102-743C47AA-3138-4545-A227-82E97BD4C92D

Q24289102-A9FA80AD-4A77-423D-A50B-9FFF5A25A7E1

Q24289102-C826C869-6FF8-4856-B6C0-919F0B998E0D

P2860

Q24289102-011D46B7-84AE-42B4-96A9-20CF77640889

Q24289102-106E2E66-CEC8-4744-8135-C88A30ADC977

Q24289102-11FD1D84-9375-4B1B-A996-206EA786C953

Q24289102-14595BBD-7342-4FC1-9A5C-FC145061CD04

Q24289102-17031BB6-E689-409B-A04F-5291C465D206

Q24289102-193A7185-2883-409B-BFF2-05F621DA20FA

Q24289102-1D4B4073-9326-4AD7-A8B1-41F89B4E87A7

Q24289102-1DC47E43-1B78-47C5-82AC-292DD28C23E2

Q24289102-1F23B63E-0D67-4551-83BB-4D4D2770A32C

Q24289102-24357101-082E-4372-A693-A55373673249

P304

Q24289102-CA781D86-F003-4A77-8E08-B5049834D409

P31

Q24289102-34AE86CF-BC0C-46E0-A693-B79FF5D3E964

P3181

Q24289102-551F56A7-0F63-417F-BAA8-2BFFBE8591CF

P356

Q24289102-A5757005-9351-4358-A460-3491470C5357

P407

Q24289102-CDFE0224-D746-4990-99DA-6CBAE2CE416E

P433

Q24289102-96753D69-8568-424D-9BCF-7FB881A7EA9D

P478

Q24289102-8392C3B6-0D5E-4FC0-8F38-FFB67C48EF70

P577

Q24289102-9E10344B-A4A9-4B3B-B8F3-7163AAC2137B

P5875

Q24289102-D8089FA5-51F7-479C-BF64-2031256D9A03

P698

Q24289102-2D92A7A3-EF21-4B0F-9AA0-B6BD100195CC

P921

Q24289102-36AC1E84-E5E7-4D35-B04F-A6D59283795A

P932

Q24289102-DD8C4861-A8B1-462E-B9CD-CED8138345CF

P3181

P356

P1433

Journal of Clinical Microbiology

P1476

Improved COBAS TaqMan Hepatiti ...... teristics in a Multisite Study

@en

P2093

A. Wang

http://www.w3.org/2001/XMLSchema#string

C. Harkleroad

http://www.w3.org/2001/XMLSchema#string

C. Sarrazin

http://www.w3.org/2001/XMLSchema#string

D. Romo

http://www.w3.org/2001/XMLSchema#string

G. Colucci

http://www.w3.org/2001/XMLSchema#string

J. Ferguson

http://www.w3.org/2001/XMLSchema#string

J. Thompson

http://www.w3.org/2001/XMLSchema#string

M. Velez

http://www.w3.org/2001/XMLSchema#string

S. Lee

http://www.w3.org/2001/XMLSchema#string

S. Soviero

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5

Evaluation of an automated sample preparation protocol for quantitative detection of hepatitis C virus RNA.

Real-Time PCR Assays for Hepatitis C Virus (HCV) RNA Quantitation Are Adequate for Clinical Management of Patients with Chronic HCV Infection

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

Hepatitis C virus infection

Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase

Clinical implications of hepatitis C viral kinetics.

Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics.

Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease

Use and interpretation of virological tests for hepatitis C.

P304

3595-3600

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2893963

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/JCM.01320-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5946894

http://www.w3.org/2001/XMLSchema#string

P698

17898157

http://www.w3.org/2001/XMLSchema#string

P921

P932

2168538

http://www.w3.org/2001/XMLSchema#string